文献速递治疗药物监测与药物基因组学药物相互作用

生理药代动力学模型识别驱动药物暴露变异的生理与分子特征

Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure.
PubMed 文献 · Clin Pharmacol Ther · 2018-04-19

本研究构建并验证了达拉非尼的生理药代动力学(PBPK)模型,模拟与观测暴露参数均值比在0.78至1.23之间。多变量分析表明,基线体重、体质指数及CYP2C8、CYP3A4和P-gp丰度可强预测稳态 trough 浓度>48 ng/mL(ROC AUC=0.94;准确率86%)。

要点

  • 达拉非尼PBPK模型在单次、多次给药及药物相互作用研究中模拟/观测比0.78–1.23。
  • 体重、BMI及CYP2C8、CYP3A4、P-gp丰度联合可预测稳态谷浓度>48 ng/mL。
  • 预测模型ROC AUC=0.94,准确率86%。

核心结论

  • 考虑基线体重、体质指数及CYP2C8、CYP3A4和P-gp丰度可强预测达拉非尼稳态谷浓度是否高于48 ng/mL。

研究设计与样本

  • 构建并验证达拉非尼的生理药代动力学模型,用于评估驱动暴露个体间变异的生理与分子特征。

主要发现

  • 单次给药、多次给药和药物相互作用研究中,达拉非尼暴露参数的模拟/观测均值比介于0.78和1.23之间。
  • 多变量分析显示基线体重、体质指数及CYP2C8、CYP3A4和P-gp丰度联合预测稳态谷浓度>48 ng/mL的ROC AUC=0.94,准确率=86%。

关键数值与推荐

  • 稳态达拉非尼谷浓度判别阈值为48 ng/mL。
  • 预测模型性能:ROC AUC=0.94,准确率=86%。

临床怎么用

  • 可利用基线体重、体质指数及CYP2C8、CYP3A4和P-gp丰度信息预测达拉非尼稳态谷浓度是否高于48 ng/mL。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prospectively defining the physiological and molecular characteristics most likely driving between-subject variability (BSV) in drug exposure provides the opportunity to inform the assessment of biomarkers to account for this variability. A physiologically based pharmacokinetic (PBPK) model was constructed and verified for dabrafenib. This model was then used to evaluate the physiological and molecular characteristics driving BSV in dabrafenib exposure. The capacity to discriminate a steady-state dabrafenib trough concentration >48 ng/mL was also evaluated. The mean simulated/observed ratios for the parameters describing dabrafenib exposure in single-dose, multiple-dose, and drug-drug interaction studies were between 0.78 and 1.23. Multivariable analysis indicated that consideration of baseline weight, body mass index, and CYP2C8, CYP3A4, and P-gp abundance strongly predicts steady-state dabrafenib trough concentration above 48 ng/mL (ROC AUC = 0.94; accuracy = 86%). This is the first study to use a verified PBPK model to identify baseline physiological and molecular characteristics driving BSV in drug exposure.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Rowland A, van Dyk M, Hopkins AM, et al. Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure. Clin Pharmacol Ther. 2018. PMID: 29574693. doi:10.1002/cpt.1076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。